EUVIMEDEUVIMED entdecken
Crossref

MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study

Julia Rotow, Umberto Malapelle, Daniel Cuadras, Núria Lara, Noelia Caro, Montserrat Roset, Montse Pedros, Yacob Pinchevsky, YongJin Kim

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.08.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Julia Rotow und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: julia_rotow@dfci.harvard.edu. Hauptthemen laut MEDLINE: Aniline Compounds, Proto-Oncogene Proteins c-met, Acrylamides, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 51 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Given the potential benefit of MET-tyrosine kinase inhibitors (TKIs) after progression on osimertinib in EGFR-mutated advanced NSCLC, evaluating real-world biomarker testing and treatment sequencing is important. We report findings from a global, direct-to-physician, survey-based chart review. PATIENTS AND METHODS: Physicians treating NSCLC were surveyed regarding rebiopsy and MET testing practices and awareness of MET overexpression and/or amplification (OverExp/Amp) cutoff levels. Biomarker testing, MET OverExp/Amp quantification and treatment sequencing were assessed in patients with EGFR-mutated advanced NSCLC with acquired MET OverExp/Amp after progression on first-line osimertinib, who received second-line treatment between January 2018 and December 2023 (data cutoff: April 8, 2025). RESULTS: Among 280 physicians, rebiopsy practices varied; the most commonly reported MET testing method was NGS (78%), followed by IHC (11%) and FISH (11%). Understanding of MET OverExp/Amp cutoff levels varied, with 35%-47% of physicians unaware of appropriate cutoffs. Among 367 patients (94% with MET Amp), MET alterations were mostly detected through tissue-based (58%) versus liquid-based tests (31%) or both (11%). MET alterations were detected using NGS (77%), then PCR (10%), IHC (10%), and FISH (4%). In 257 patients with MET cutoff data available, most MET Amp had gene copy numbers ≥6 (88%). MET-TKIs (29%) and EGFR-TKIs (24%) were the most common second-line treatments, followed by chemotherapy (20%). Of 193 patients with high MET levels, most received targeted treatments (MET-TKI 35%, EGFR-TKI 23%). CONCLUSION: Rebiopsy practices and knowledge of MET OverExp/Amp cutoffs varied among physicians. IHC/FISH were underutilized; however, their use should be encouraged for optimal patient identification and treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsProto-Oncogene Proteins c-metAcrylamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansPyrimidinesIndolesErbB ReceptorsMutationFemaleDisease ProgressionGene AmplificationMaleProtein Kinase InhibitorsBiomarkers, TumorMiddle Aged

Stichwörter der Autor:innen

EGFR-mutated NSCLCFISHIHCMET amplificationMET overexpressionOsimertinibReal-world evidence

Substanzen

PyrimidinesAniline CompoundsProto-Oncogene Proteins c-metAcrylamidesIndolesosimertinibErbB ReceptorsMET protein, humanEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: julia_rotow@dfci.harvard.edu.
  • Department of Public Health, University of Naples Federico II, Naples, Italy.
  • Real World Solutions, IQVIA, Barcelona, Spain.
  • Global Medical Affairs, AstraZeneca, Gaithersburg, MD.
  • Oncology Outcomes Research, AstraZeneca, Mississauga, ON, Canada.

Förderung

  • AstraZeneca

Zitieren

APA

Rotow, J., Malapelle, U., Cuadras, D., Lara, N., Caro, N., Roset, M., Pedros, M., Pinchevsky, Y., & Kim, Y. (2026). MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.08.011

Vancouver

Rotow J, Malapelle U, Cuadras D, Lara N, Caro N, Roset M, et al. MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.08.011

BibTeX
@article{Rotow2026,
  author = {Rotow, Julia and Malapelle, Umberto and Cuadras, Daniel and Lara, Núria and Caro, Noelia and Roset, Montserrat and Pedros, Montse and Pinchevsky, Yacob and Kim, YongJin},
  title = {MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.08.011}
}
Kostenlos starten →